Global Health Data Exchange - Discover the World's Health Data

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

Nav

General Info
Geography 
Argentina (ARG)
Australia (AUS)
Austria (AUT)
Belgium (BEL)
Brazil (BRA)
Canada (CAN)
China (CHN)
Hong Kong
Czechia (CZE)
Denmark (DNK)
Finland (FIN)
France (FRA)
Germany (DEU)
Greece (GRC)
Hungary (HUN)
Ireland (IRL)
Italy (ITA)
Malaysia (MYS)
Mexico (MEX)
Norway (NOR)
Poland (POL)
Portugal (PRT)
Singapore (SGP)
Slovakia (SVK)
Spain (ESP)
Sweden (SWE)
Thailand (THA)
Turkey (TUR)
Ukraine (UKR)
Time period covered 
01/2001 - 12/2008
Citation
Authors 
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P
Journal 
Lancet
Volume 
372
Issue 
9644
Pages 
1174–83
Publication year 
2008
Suggested citation 
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644): 1174–83.